Patents by Inventor Zhifei FU

Zhifei FU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTAL FORMS OF PYRIDOPYRAZOLE COMPOUNDS AND PREPARATION METHOD THEREFOR
    Publication number: 20230365596
    Abstract: Provided are crystal forms of compounds represented by formula(II)-formula (VIII) and formula (I)-formula (VIII-1), a preparation method therefor and an application of the compounds and crystal forms in the preparation of a drug for treating a related disease.
    Type: Application
    Filed: September 26, 2021
    Publication date: November 16, 2023
    Inventors: Jiansong WANG, Zhifei FU, Zhibo LUO, Miaorong LUO, Yang ZHANG, Jian LI, Shuhui CHEN, Yingxia BAO, Wei WANG, Zhoufan XIE
  • Crystal forms C and E of pyrazin-2(1H)-one compound and preparation method therefor
    Patent number: 11680061
    Abstract: A crystal form of a pyrazin-2(1H)-one compound and a preparation method therefor. The present invention specifically related to a compound of formula (II) and a preparation method for a crystal form of the compound.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: June 20, 2023
    Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD.
    Inventors: Fei Hong, Jinming Huang, Longhui Gao, Shicong Wang, Tingting Yin, Zhifei Fu, Miaorong Luo, Yang Zhang, Jian Li, Shuhui Chen
  • DEUTERATED THIENOPYRIDINE COMPOUND
    Publication number: 20230094146
    Abstract: Disclosed is a deuterated thienopyridine compound. Specifically disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 7, 2021
    Publication date: March 30, 2023
    Inventors: Zhifei FU, Miaorong LUO, Yang ZHANG, Jian LI, Shuhui CHEN
  • Crystalline form and B crystalline form of pyrazine-2(1H)-ketone compound and preparation method thereof
    Patent number: 11603366
    Abstract: Provided are crystalline forms of pyrazine-2(1H)-ketone compound and a preparation method thereof; specifically disclosed are a method for preparing the compound of formula (II) and crystalline forms thereof.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: March 14, 2023
    Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD.
    Inventors: Juan Yu, Fei Hong, Tingting Yin, Zhiliang Chen, Yichao Zhuang, Zhifei Fu, Miaorong Luo, Yang Zhang, Jian Li, Shuhui Chen
  • Crystal form D of pyrazine-2(1H)-ketone compound and preparation method therefor
    Patent number: 11597722
    Abstract: The present invention disclosed a crystal form of pyrazine-2(1H)-ketone compound and a preparation method therefor. Specifically disclosed is a method for preparing a compound of formula (II) and a crystal form thereof.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: March 7, 2023
    Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD.
    Inventors: Zhiliang Chen, Zhiyi Luo, Yichao Zhuang, Jinxia Lin, Longhui Gao, Zhifei Fu, Miaorong Luo, Yang Zhang, Jian Li, Shuhui Chen
  • Pyrazine-2(1H)-ketone compound preparation method
    Patent number: 11535609
    Abstract: Provided are preparation methods for the chemical compound represented by formula (I) and an intermediate thereof.
    Type: Grant
    Filed: August 4, 2020
    Date of Patent: December 27, 2022
    Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD.
    Inventors: Jinming Huang, Juan Yu, Jinxia Lin, Limei Yang, Jinxiang Zeng, Zhifei Fu, Miaorong Luo, Yang Zhang, Jian Li, Shuhui Chen
  • PYRAZINE-2(1H)-KETONE COMPOUND PREPARATION METHOD
    Publication number: 20220380350
    Abstract: Provided are preparation methods for the chemical compound represented by formula (I) and an intermediate thereof.
    Type: Application
    Filed: August 4, 2020
    Publication date: December 1, 2022
    Inventors: Jinming HUANG, Juan YU, Jinxia LIN, Limei YANG, Jinxiang ZENG, Zhifei FU, Miaorong LUO, Yang ZHANG, Jian LI, Shuhui CHEN
  • A CRYSTALLINE FORM AND B CRYSTALLINE FORM OF PYRAZINE-2(1H)-KETONE COMPOUND AND PREPARATION METHOD THEREOF
    Publication number: 20220315559
    Abstract: Provided are crystalline forms of pyrazine-2(1H)-ketone compound and a preparation method thereof; specifically disclosed are a method for preparing the compound of formula (II) and crystalline
    Type: Application
    Filed: August 4, 2020
    Publication date: October 6, 2022
    Inventors: Juan YU, Fei HONG, Tingting YIN, Zhiliang CHEN, Yichao ZHUANG, Zhifei FU, Miaorong LUO, Yang ZHANG, Jian LI, Shuhui CHEN
  • CRYSTAL FORMS C AND E OF PYRAZIN-2(1H)-ONE COMPOUND AND PREPARATION METHOD THEREFOR
    Publication number: 20220289722
    Abstract: A crystal form of a pyrazin-2(1H)-one compound and a preparation method therefor. The present invention specifically related to a compound of formula (II) and a preparation method for a crystal form of the compound.
    Type: Application
    Filed: August 4, 2020
    Publication date: September 15, 2022
    Inventors: Fei HONG, Jinming HUANG, Longhui GAO, Shicong WANG, Tingting YIN, Zhifei FU, Miaorong LUO, Yang ZHANG, Jian LI, Shuhui CHEN
  • CRYSTAL FORM D OF PYRAZINE-2(1H)-KETONE COMPOUND AND PREPARATION METHOD THEREFOR
    Publication number: 20220281853
    Abstract: Disclosed are a crystal form of pyrazine-2(1H)-ketone compound and a preparation method therefor. Specifically disclosed is a method for preparing a compound of formula (II) and a crystal form thereof.
    Type: Application
    Filed: August 4, 2020
    Publication date: September 8, 2022
    Inventors: Zhiliang CHEN, Zhiyi LUO, Yichao ZHUANG, Jinxia LIN, Longhui GAO, Zhifei FU, Miaorong LUO, Yang ZHANG, Jian LI, Shuhui CHEN
  • NITROGEN-CONTAINING SPIRO DERIVATIVE AS RET INHIBITOR
    Publication number: 20220204507
    Abstract: Disclosed are a series of compounds with a nitrogen-containing spiro structure and an application thereof in the preparation of an RET kinase inhibitor. Specifically, disclosed is a compound as shown in formula (II) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 3, 2020
    Publication date: June 30, 2022
    Applicants: GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY, MEDSHINE DISCOVERY INC.
    Inventors: Jiansong WANG, Zhifei FU, Zhibo LUO, Miaorong LUO, Yang ZHANG, Yalei CAI, Wu ZHU, Jian LI, Shuhui CHEN, Yingxia BAO, Wei WANG, Zhoufan XIE
  • FGFR INHIBITOR COMPOUND IN SOLID FORM AND PREPARATION METHOD THEREFOR
    Publication number: 20220177475
    Abstract: Disclosed are the solid form, crystalline form, crystal form A of a compound of formula (I), and a preparation method therefor, crystal form B and a preparation method therefor. Also disclosed are use of the solid form, crystalline form, crystal form A, and crystal form B in the preparation of drugs for the treatment of diseases related to FGFR.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 9, 2022
    Applicant: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD
    Inventors: Zhifei FU, Miaorong LUO, Jikui SUN, Yang ZHANG, Jian LI, Shuhui CHEN
  • Pyrazine-2(1H)-ketone compound acting as FGFR inhibitor
    Patent number: 11286248
    Abstract: Disclosed are a compound as shown in formula (I), and an isomer thereof or a pharmaceutically acceptable salt thereof, and involved is the use thereof in the preparation of drugs for treating FGFR-associated diseases.
    Type: Grant
    Filed: February 2, 2019
    Date of Patent: March 29, 2022
    Assignee: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD.
    Inventors: Yang Zhang, Zhifei Fu, Miaorong Luo, Zaifang Ren, Dongjie Hu, Jie Li, Jian Li, Shuhui Chen
  • PYRAZINE-2(1H)-KETONE COMPOUND ACTING AS FGFR INHIBITOR
    Publication number: 20210040070
    Abstract: Disclosed are a compound as shown in formula (I), and an isomer thereof or a pharmaceutically acceptable salt thereof, and involved is the use thereof in the preparation of drugs for treating FGFR-associated diseases.
    Type: Application
    Filed: February 2, 2019
    Publication date: February 11, 2021
    Applicant: ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD.
    Inventors: Yang ZHANG, Zhifei FU, Miaorong LUO, Zaifang REN, Dongjie HU, Jie LI, Jian LI, Shuhui CHEN
  • Tyrosine kinase inhibitor and pharmaceutical composition comprising same
    Patent number: 10654808
    Abstract: The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: May 19, 2020
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Chaofeng Long, Zhengxia Chen, Xiaoxin Chen, Yang Zhang, Zhuowei Liu, Peng Li, Shuhui Chen, Guibai Liang, Cheng Xie, Zhengwei Li, Zhifei Fu, Guoping Hu, Jian Li
  • IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF
    Publication number: 20190169140
    Abstract: A compound as an indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, and an application thereof in the field of IDO1-related diseases, and in particular a compound as shown in formula (I) and a pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 6, 2019
    Inventors: Yang ZHANG, Zhifei FU, Miaorong LUO, Jian LI, Shuhui CHEN
  • TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    Publication number: 20190119217
    Abstract: The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same.
    Type: Application
    Filed: April 7, 2016
    Publication date: April 25, 2019
    Inventors: Chaofeng LONG, Zhengxia CHEN, Xiaoxin CHEN, Yang ZHANG, Zhuowei LIU, Peng LI, Shuhui CHEN, Guibai LIANG, Cheng XIE, Zhengwei LI, Zhifei FU, Guoping HU, Jian LI
  • Benzofuran analogue as NS4B inhibitor
    Patent number: 10100027
    Abstract: Provided is a benzofuran analog having a structure represented by formula (I) and used as an NS4B inhibitor, or a pharmaceutically acceptable salt of the benzofuran analog. The benzofuran analog has anti-hepatitis C virus activity.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: October 16, 2018
    Assignees: CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD., SICHUAN UNIVERSITY
    Inventors: Yang Zhang, Zhifei Fu, Jianfei Wang, Jian Li, Shuhui Chen, Yuquan Wei, Luoting Yu, Xin Tao
  • BENZOFURAN ANALOGUE AS NS4B INHIBITOR
    Publication number: 20170240519
    Abstract: Provided is a benzofuran analogue having a structure represented by formula (I) and used as an NS4B inhibitor, or a pharmaceutically acceptable salt of the benzofuran analogue. The benzofuran analogue has anti-hepatitis C virus activity.
    Type: Application
    Filed: September 23, 2015
    Publication date: August 24, 2017
    Inventors: Yang ZHANG, Zhifei FU, Jianfei WANG, Jian LI, Shuhui CHEN, Yuquan WEI, Luoting YU, Xin TAO